INBX
Inhibrx Biosciences Inc
NASDAQ · Biotechnology
$83.91
+2.38 (+2.92%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 193.4K | 639.7K | 390.65M | 384.43M | 347.35M |
| Net Income | 1.64B | 4.87B | -113,394,480 | -115,444,062 | -82,575,244 |
| EPS | — | — | — | — | — |
| Profit Margin | 843,786.0% | 801,596.7% | -29.0% | -30.0% | -23.8% |
| Rev Growth | -69.8% | -69.8% | +1.5% | -5.8% | +11.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 100.76M | 85.85M | 85.10M |
| Total Equity | — | — | 850.86M | 832.96M | 791.72M |
| D/E Ratio | — | — | 0.12 | 0.10 | 0.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 1.64B | 5.16B | -167,670,996 | -155,644,267 | -144,289,075 |
| Free Cash Flow | — | — | -86,634,001 | -85,235,104 | -84,943,791 |